info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Diabetes Companies

India has a growing healthcare sector, and several companies are actively involved in diabetes care. Diabetes is a prevalent chronic condition in India, and companies in this space aim to provide a range of products and services to support diabetes management.

India Diabetes Key CompaniesLatest India Diabetes Companies Companies Update



  • August 2023: Saxagliptin 2.5 mg and 5 mg tablets, which are generic equivalents of Onglyza, a diabetes medication developed by AstraZeneca, were approved by the U.S. Food and Drug Administration (FDA) in August 2023. Aurobindo Pharma and Glenmark Pharmaceuticals, respectively, obtained final FDA approval. In a press release announcing final approval to manufacture and market the bioequivalent and therapeutically equivalent product to the reference-listed drug Onglyza 2.5 mg and 5 mg tablets, 




  • August 2023: A pharmaceutical company, Akums Drugs and Pharmaceuticals Limited, recently introduced a novel formulation in August 2023. This formulation is designed to treat Type-2 Diabetes and is intended for the senior population. The new combination drug, as stated by Akums Drugs and Pharmaceuticals Limited, is intended to provide effective glycemic control for patients with diabetes. The Drug Controller General of India (DCGI) has reportedly approved the treatment, which the company refers to as a "groundbreaking therapy" for the elderly with the disease. Commonly prescribed for the management of diabetes, Vildagliptin SR and Metformin SR will be combined to form the new treatment.




  • November 2023: USV and Biogenomics jointly declared the introduction of INSUQUICK, a biosimilar insulin aspart, in November 2023. "InsuQuick is a "Make in India" product, having been developed and manufactured entirely with indigenous technology, and having undergone a rigorous clinical program to ensure global quality standards," according to a company statement. It is accessible in Tier I/II cities and all metropolitan areas. Cartridges, vials, and prefilled disposable pens will be offered for Insuquick, providing diabetics with a degree of adaptability.


List of India Diabetes Companies Key companies in the market

  • Novo Nordisk A/S (Denmark)

  • USV Private Limited (India)

  • sanofi-aventis U.S

  • LLC (US)

  • Novartis AG (Switzerland)

  • Merck & Co., Inc. (US)

  • Becton Dickinson and Company (US)

  • Roche Diabetes Care, Inc.(US),

  • Johnson & Johnson Services, Inc.(us)

  • Bayer AG (Germany)

  • Ypsomed (Switzerland)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.